The European Patent Office intends to grant Scancell Holdings plc's (LON: SCLP) patent application for its Moditope immunotherapy platform, Proactive Investors reported on Friday.

When the patent is formally granted it will provide protection for the company's pipeline of Moditope vaccines.

Scancell believes the vaccines could help revolutionise the way cancer is treated. It said the patent was key as it works on progressing development of the platform.

The patent will cover the major areas in Europe and similar filings have been made in Australia, Brazil, Canada, China, Hong Kong, Japan, South Korea, South Africa and the US.

Chief executive Cliff Holloway said the European Patent Office's confirmation of its intention to grant the patent application showed it continued "to uphold the validity of Scancell's expanding patent estate."